CCR2 and prostate cancer: In a preclinical study using mouse transplanted with a cabazitaxel-resistant prostate cancer cell line, inhibition of the CCL2–CCR2 axis released cabazitaxel-resistance and suppressed tumor growth in mice treated concurrently with cabazitaxel and CCR2 antagonist [30].